131 related articles for article (PubMed ID: 31959902)
1. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers.
Malouf GG; Flippot R; Dong Y; Dinatale RG; Chen YB; Su X; Compérat E; Rouprêt M; Mano R; Blum KA; Yao H; Mouawad R; Spano JP; Khayat D; Karam JA; Ho TH; Tickoo SK; Russo P; Hsieh JJ; Tannir NM; Hakimi AA
Sci Rep; 2020 Jan; 10(1):701. PubMed ID: 31959902
[TBL] [Abstract][Full Text] [Related]
2. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
Malouf GG; Ali SM; Wang K; Balasubramanian S; Ross JS; Miller VA; Stephens PJ; Khayat D; Pal SK; Su X; Sircar K; Tamboli P; Jonasch E; Tannir NM; Wood CG; Karam JA
Eur Urol; 2016 Aug; 70(2):348-57. PubMed ID: 26895810
[TBL] [Abstract][Full Text] [Related]
3. YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.
White SM; Avantaggiati ML; Nemazanyy I; Di Poto C; Yang Y; Pende M; Gibney GT; Ressom HW; Field J; Atkins MB; Yi C
Dev Cell; 2019 May; 49(3):425-443.e9. PubMed ID: 31063758
[TBL] [Abstract][Full Text] [Related]
4. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
6. The Hippo pathway member Nf2 is required for inner cell mass specification.
Cockburn K; Biechele S; Garner J; Rossant J
Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
[TBL] [Abstract][Full Text] [Related]
7. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
8. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
9. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of the Hippo Pathway in Lung Cancers: Clinical Implications.
Teoh SL; Das S
Curr Drug Targets; 2017 Nov; 18(16):1880-1892. PubMed ID: 27628948
[TBL] [Abstract][Full Text] [Related]
11. Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling.
Chen Z; Li S; Mo J; Hawley E; Wang Y; He Y; Brosseau JP; Shipman T; Clapp DW; Carroll TJ; Le LQ
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 32960816
[TBL] [Abstract][Full Text] [Related]
12. Sarcomatoid renal cell carcinoma of papillary origin. A case report and cytogenic evaluation.
Cohen RJ; McNeal JE; Susman M; Sellner LN; Iacopetta BJ; Weinstein SL; Dawkins HJ
Arch Pathol Lab Med; 2000 Dec; 124(12):1830-2. PubMed ID: 11100068
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/BARD1-dependent ubiquitination of NF2 regulates Hippo-YAP1 signaling.
Verma S; Yeddula N; Soda Y; Zhu Q; Pao G; Moresco J; Diedrich JK; Hong A; Plouffe S; Moroishi T; Guan KL; Verma IM
Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7363-7370. PubMed ID: 30918126
[TBL] [Abstract][Full Text] [Related]
14. Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney.
Mehra R; Vats P; Cieslik M; Cao X; Su F; Shukla S; Udager AM; Wang R; Pan J; Kasaian K; Lonigro R; Siddiqui J; Premkumar K; Palapattu G; Weizer A; Hafez KS; Wolf JS; Sangoi AR; Trpkov K; Osunkoya AO; Zhou M; Giannico G; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
Cancer Discov; 2016 Nov; 6(11):1258-1266. PubMed ID: 27604489
[TBL] [Abstract][Full Text] [Related]
15. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma.
Zhao F; Yang Z; Chen Y; Zhou Q; Zhang J; Liu J; Wang B; He Q; Zhang L; Yu Y; Liu P
World Neurosurg; 2018 Sep; 117():e269-e279. PubMed ID: 29902598
[TBL] [Abstract][Full Text] [Related]
18. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
[TBL] [Abstract][Full Text] [Related]
19. Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix.
Kim SH; Basili T; Dopeso H; Da Cruz Paula A; Bi R; Issa Bhaloo S; Pareja F; Li Q; da Silva EM; Zhu Y; Hoang T; Selenica P; Murali R; Chan E; Wu M; Derakhshan F; Maroldi A; Hanlon E; Ferreira CG; Lapa E Silva JR; Abu-Rustum NR; Zamarin D; Chandarlapaty S; Matrai C; Yoon JY; Reis-Filho JS; Park KJ; Weigelt B
J Pathol; 2022 Aug; 257(5):635-649. PubMed ID: 35411948
[TBL] [Abstract][Full Text] [Related]
20. Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent.
Hikasa H; Sekido Y; Suzuki A
Cell Rep; 2016 Mar; 14(12):2950-61. PubMed ID: 26997273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
